Patritumab Deruxtecan
First-line combination should be ‘new standard’ in advanced lung cancer
The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the randomized phase 3 MARIPOSA trial.
VIDEO: Future use of antibody-drug conjugates in EGFR-mutated lung cancer
In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, highlights potential treatments options coming to the EGFR-mutated lung cancer space.
Patritumab deruxtecan extends PFS vs. chemotherapy in advanced non-small cell lung cancer
Patritumab deruxtecan improved PFS compared with chemotherapy among certain patients with advanced non-small cell lung cancer, according to the agent’s manufacturer.
VIDEO: 'Exciting' areas of research in metastatic breast cancer
Healio spoke with Sara M. Tolaney, MD, MPH, about the latest research in metastatic breast cancer.
FDA grants breakthrough therapy status to patritumab deruxtecan for lung cancer subset
The FDA granted breakthrough therapy designation to patritumab deruxtecan for treatment of certain patients with non-small cell lung cancer.
Patritumab deruxtecan demonstrates antitumor activity in patients with EGFR-mutant NSCLC
Patritumab deruxtecan induced a 39% overall response rate among patients with advanced, EGFR-mutant non-small cell lung cancer, according to phase 1 study results presented during the virtual ASCO Annual Meeting.